20 Dec ABLE 2023 Recap: a look back at the 12 most important moments of the year
As we approach the last days of 2023, it is time to look back at the milestones achieved and the most important moments of the year. We also want to take this opportunity to recognize all the great work and efforts of the ABLE Human Motion team, as well as the valuable support of our pilots, clinical partners and investors. Your contribution has been key to achieving important milestones, thank you! 🙂
The year 2022 finished with a very important milestone: Clinical Trials with the ABLE Exoskeleton were completed successfully in leading hospitals of Germany, Netherlands and Spain, and the Results were published in 2 high-impact scientific journals.
This is how we started, but now…
Let’s dive into the 12 most important moments of our year 2023:
Presence at Mobile World Congress 2023, with real demos of a pilot that walked +7km & played ping-pong with the King of Spain, Felipe VI.
Closed a Bridge Round of 850k€ with private investors to finance the road towards the CE mark and the transfer to production.
Electromagnetic compatibility and electrical safety testing were passed in a certified laboratory.
Technical File (TF) as a medical device compiled and submitted to the Regulatory Body British Standards Institution (BSI).
Medical Device Regulation (MDR) CE Certification Audit completed successfully.
10 first Pre-Orders of the exoskeleton were received from clinical institutions that committed to purchase the device.
Positive international PCT search report for our Patent that protections our innovative Backdrivable Actuator.
Video presenting the main features of the ABLE Exoskeleton was launched.
Participation at ISCoS 2023, the leading event for clinical and research professionals in the SCI and neurorehabilitation field.
Celebration of the 5 years of the company and Inauguration of our New Facilities in Barcelona.
ABLE Exoskeleton tested by +200 patients, that walked +400,000 steps.
Responses to TF Round 1 Review sent to Regulatory Body BSI (technical and clinical parts).
The path towards the democratization of exoskeleton technology requires moving forward with determination and long-term vision, obtaining the necessary certifications, demonstrating the efficacy of the ABLE system, and cooperating with multiple stakeholders and partners. A road to become the standard of care, enabling widespread access to robotic rehabilitation.
But, what’s next for 2024?
- Regulatory Approval in Europe (CE-mark): expected for March 2024.
- Production of the first units at our new facilities in Barcelona.
- First sales of the ABLE Exoskeleton for clinical use.
- New product indications.
- Development of a breakthrough exoskeleton for home & community use.
- … And many more!